<?xml version='1.0' encoding='utf-8'?>
<document id="23773422"><sentence text="Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences."><entity charOffset="32-43" id="DDI-PubMed.23773422.s1.e0" text="clopidogrel" /></sentence><sentence text="Clopidogrel is a prodrug that needs to be activated to inhibit platelet aggregation"><entity charOffset="0-11" id="DDI-PubMed.23773422.s2.e0" text="Clopidogrel" /></sentence><sentence text=" The objective of this study was to evaluate the prevalence and clinical consequences of potential drug-drug interactions of clopidogrel with drugs affecting CYP3A4 activity"><entity charOffset="125-136" id="DDI-PubMed.23773422.s3.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Co-administrations of clopidogrel together with well-established CYP3A4 inhibitors, CYP3A4 inducers, and atorvastatin were investigated in a population-based pharmacoepidemiological study utilizing data from the national healthcare registers and in more detail from a university hospital register in Finland"><entity charOffset="22-33" id="DDI-PubMed.23773422.s5.e0" text="clopidogrel" /><entity charOffset="105-117" id="DDI-PubMed.23773422.s5.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.23773422.s5.e0" e2="DDI-PubMed.23773422.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23773422.s5.e0" e2="DDI-PubMed.23773422.s5.e1" /></sentence><sentence text=" The main outcome measures were all-cause mortality and mortality and morbidity related to thrombosis or bleeding" /><sentence text="" /><sentence text="In the nationwide analysis, 6" /><sentence text="1%, 1" /><sentence text="0%, and 20" /><sentence text="8% of the clopidogrel-treated patients were exposed to concomitant use of CYP3A4 inhibitors, CYP3A4 inducers, and atorvastatin, respectively"><entity charOffset="10-21" id="DDI-PubMed.23773422.s11.e0" text="clopidogrel" /><entity charOffset="114-126" id="DDI-PubMed.23773422.s11.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.23773422.s11.e0" e2="DDI-PubMed.23773422.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23773422.s11.e0" e2="DDI-PubMed.23773422.s11.e1" /></sentence><sentence text=" In the survival analysis, the adjusted hazard ratio for overall mortality was 2" /><sentence text="29 (P &lt; 0" /><sentence text="001) for CYP3A4 inducer users and 0" /><sentence text="74 (P = 0" /><sentence text="003) for atorvastatin users compared with controls (patients receiving clopidogrel without interacting medication)"><entity charOffset="9-21" id="DDI-PubMed.23773422.s16.e0" text="atorvastatin" /><entity charOffset="71-82" id="DDI-PubMed.23773422.s16.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23773422.s16.e0" e2="DDI-PubMed.23773422.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23773422.s16.e0" e2="DDI-PubMed.23773422.s16.e1" /></sentence><sentence text=" CYP3A4 inhibitor use seemed to prevent from thrombosis: HR 0" /><sentence text="67, P &lt; 0" /><sentence text="001" /><sentence text=" The hospitalizations due to bleedings were rarer in atorvastatin and CYP3A4 inhibitor groups compared with controls"><entity charOffset="53-65" id="DDI-PubMed.23773422.s20.e0" text="atorvastatin" /></sentence><sentence text=" Thrombosis complications leading to hospitalizations were more often seen in the atorvastatin group than in the control group"><entity charOffset="82-94" id="DDI-PubMed.23773422.s21.e0" text="atorvastatin" /></sentence><sentence text="" /><sentence text="No uniform untoward effect of concomitant CYP3A4 inhibitor use on the clinical efficacy of clopidogrel was found"><entity charOffset="91-102" id="DDI-PubMed.23773422.s23.e0" text="clopidogrel" /></sentence><sentence text=" In patients receiving concomitant atorvastatin and clopidogrel, the antithrombotic effect of clopidogrel was moderately attenuated, but the combination significantly reduced the overall mortality"><entity charOffset="35-47" id="DDI-PubMed.23773422.s24.e0" text="atorvastatin" /><entity charOffset="52-63" id="DDI-PubMed.23773422.s24.e1" text="clopidogrel" /><entity charOffset="94-105" id="DDI-PubMed.23773422.s24.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23773422.s24.e0" e2="DDI-PubMed.23773422.s24.e0" /><pair ddi="false" e1="DDI-PubMed.23773422.s24.e0" e2="DDI-PubMed.23773422.s24.e1" /><pair ddi="false" e1="DDI-PubMed.23773422.s24.e0" e2="DDI-PubMed.23773422.s24.e2" /><pair ddi="false" e1="DDI-PubMed.23773422.s24.e1" e2="DDI-PubMed.23773422.s24.e1" /><pair ddi="false" e1="DDI-PubMed.23773422.s24.e1" e2="DDI-PubMed.23773422.s24.e2" /></sentence><sentence text=" CYP3A4 inhibitors and atorvastatin may reduce bleedings in clopidogrel users"><entity charOffset="23-35" id="DDI-PubMed.23773422.s25.e0" text="atorvastatin" /><entity charOffset="60-71" id="DDI-PubMed.23773422.s25.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23773422.s25.e0" e2="DDI-PubMed.23773422.s25.e0" /><pair ddi="false" e1="DDI-PubMed.23773422.s25.e0" e2="DDI-PubMed.23773422.s25.e1" /></sentence><sentence text="" /></document>